328
Participants
Start Date
May 31, 2013
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
emtricitabine 200mg/tenofovir 300mg
The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
L.A. Gay and Lesbian Center, Los Angeles
The OASIS Clinic, Los Angeles
Los Angeles County Department of Public Health
OTHER_GOV
Los Angeles LGBT Center
OTHER
The OASIS Clinic
UNKNOWN
AIDS Project Los Angeles
OTHER
University of California, Los Angeles
OTHER